所有图片(3)

文件

O5015

盐酸奥昔布宁

Name: 盐酸奥昔布宁
Brand: SIAL

meets EP, USP testing specifications

别名:

α-苯基环己烷乙醇酸 4-(二乙基氨基)-2-丁炔酯盐酸盐

登录查看公司和协议定价

所有图片(3)

About This Item

经验公式（希尔记法）:

C₂₂H₃₁NO₃ · HCl

CAS号:

1508-65-2

分子量:

393.95

EC號碼:

216-139-7

MDL號碼:

MFCD00072150

分類程式碼代碼:

12161900

PubChem物質ID:

24898008

NACRES:

NA.21

推荐产品

Slide 1 of 10

1 of 10

Sigma-Aldrich

O2881

盐酸奥昔布宁

USP

1485103

盐酸奥昔布宁

Supelco

PHR2547

盐酸奥昔布宁

Sigma-Aldrich

O4264

骨桥蛋白人

$牛血清白蛋白来源于牛血清 heat shock fraction, pH 7, ≥98%$

Sigma-Aldrich

A7906

牛血清白蛋白来源于牛血清

Sigma-Aldrich

B7148

丁螺环酮盐酸盐盐酸盐

O0288000

奥昔布宁盐酸盐

Sigma-Aldrich

B9688

苯噻啶

Supelco

PHR1379

硫酸阿托品

$牛血清白蛋白来源于牛血清 heat shock fraction, pH 7, ≥98%$

Sigma-Aldrich

A9647

牛血清白蛋白来源于牛血清

agency

USP/NF
meets EP testing specifications
meets USP testing specifications

品質等級

200

形狀

solid

應用

pharmaceutical (small molecule)

儲存溫度

room temp

SMILES 字串

Cl.CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c2ccccc2

InChI

1S/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H

InChI 密鑰

SWIJYDAEGSIQPZ-UHFFFAOYSA-N

基因資訊

human ... CHRM2(1129) , CHRM3(1131)

正在寻找类似产品? 访问产品对比指南

生化／生理作用

毒蕈碱型乙酰胆碱受体拮抗剂；可能通过下调生长促进基因，抑制膀胱平滑肌细胞的增殖。

PHR2547

盐酸奥昔布宁, certified reference material, pharmaceutical secondary standard

象形圖

GHS07

訊號詞

Warning

危險聲明

H302

防範說明

P264 - P270 - P301 + P312 - P501

危險分類

Acute Tox. 4 Oral

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Early administration of oxybutynin improves bladder function and clinical outcomes in newborns with posterior urethral valves.

Jessica T Casey et al.

The Journal of urology, 188(4 Suppl), 1516-1520 (2012-08-23)

Abnormal bladder function following posterior urethral valve ablation can lead to deleterious effects on renal function and urinary continence. We performed a pilot study to determine if bladder dysfunction could be ameliorated by the early administration of oxybutynin. We enrolled

Bryophyllum pinnatum inhibits detrusor contractility in porcine bladder strips--a pharmacological study towards a new treatment option of overactive bladder.

V Schuler et al.

Phytomedicine : international journal of phytotherapy and phytopharmacology, 19(10), 947-951 (2012-07-25)

A broad spectrum of synthetic agents is available for the treatment of overactive bladder. Anti-cholinergic drugs show a poor compliance due to side effects. There is an increasing use of plant extracts in medicine. We have therefore investigated the inhibitory

Clinical effectiveness of early treatment with hyperbaric oxygen therapy for severe late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation in pediatric patients.

Daniele Zama et al.

Pediatric transplantation, 17(1), 86-91 (2012-12-13)

HC is a possible cause of morbidity and extended hospitalization after HSCT. Recent studies have reported the efficiency of HOT in adult patients who underwent allogeneic HSCT, but data in children are scarce. We report our single center experience with

Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guérin treatment.

Michael H Johnson et al.

The Journal of urology, 189(4), 1268-1274 (2012-11-06)

Intravesical bacillus Calmette-Guérin is used to decrease recurrence rates of nonmuscle invasive urothelial carcinoma. Irritative urinary symptoms are a common side effect of treatment and frequently limit treatment tolerance. While anticholinergic medications may be used for symptom prophylaxis, to our

Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin.

Naoki Aizawa et al.

European urology, 62(6), 1165-1173 (2012-09-18)

Mirabegron is the first β3-adrenoceptor agonist that is clinically effective for overactive bladder. The effects of mirabegron on primary bladder mechanosensitive single-unit afferent activities (SAAs) and bladder microcontractions were evaluated and compared with the effects of oxybutynin. Female Sprague-Dawley rats

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

文件

盐酸奥昔布宁